The global leukemia therapeutics market size was estimated to be USD 16.35 billion in 2023 and is expected to reach at USD 35.28 billion by 2034 with a CAGR of 7.24% during the forecast period 2024-2034. Growing prevalence of leukemia, increasing awareness regarding to early detection & treatment of leukemia, surge in investment in healthcare sector, rising focus on the development of novel & effective drugs, growing research & development activities, increasing need for more effective treatment, surge in number of clinical trials by key market players, and rising approval of novel drugs for leukaemia by regulatory authorities are some of the key factors boosting the market growth.
Rising approval of novel drugs for leukaemia by regulatory authorities is predicted to boost the market growth during the forecast period. Leukemia is a form of blood cancer characterized by the abnormal growth of leukocytes. Acute and chronic leukemia are the two categories of leukemia. This condition leads to a shortage of healthy blood cells, resulting in various symptoms like bleeding, bruising, bone pain, fatigue, and fever. Consequently, industry stakeholders are concentrating on the creation of novel treatment alternatives. For instance, in May 2022, Servier has obtained approval from the US FDA for TIBSOVO (ivosidenib tablets) to be used in combination with azacitidine for treating newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults aged 75 years or older, or in those with medical conditions that make them unsuitable for intensive induction chemotherapy.
By type, chronic myeloid leukaemia was the highest revenue-grossing segment in the global leukemia therapeutics market in 2023 owing to rising prevalence of chronic myeloid leukaemia, growing geriatric population, and increasing funding for research & development activities. Additionally, chronic lymphocytic leukaemia is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of chronic lymphocytic leukaemia and surge in approvals by regulatory bodies. For instance, in November 2022, The use of Brukinsa (zanubrutinib) in the treatment of adult patients with either treatment-naive (TN) or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) has been approved by the European Council, according to information released by BeiGene.
By treatment, chemotherapy was the highest revenue-grossing segment in the global leukemia therapeutics market in 2023 owing to the growing prevalence of leukemia cases, rising focus on development of novel products for the treatment of leukaemia, and increasing approvals by regulatory bodies. For instance, in October 2022, The US FDA has granted approval for Quizartinib to be used in conjunction with standard cytarabine and anthracycline induction, as well as standard cytarabine consolidation chemotherapy. It is also approved for use as a continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD-positive acute myeloid leukemia (AML). Additionally, targeted therapy is predicted to grow at fastest CAGR during the forecast period owing to the fewer side effects of this therapy, rising demand for targeted drugs, and increasing launch of novel drugs.
By route of administration, injectable was the highest revenue-grossing segment in the global leukemia therapeutics market in 2023 owing to the increasing research & development activities and surge in clinical trial procedures. For instance, in October 2023, Syndax Pharmaceuticals has reported that Revumenib has successfully achieved its objectives in the trial, potentially paving the way for the drug's introduction to the market. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to the ease of administration and growing focus on development of new drugs.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global leukemia therapeutics market in 2023 owing to the increasing awareness regarding leukemia & treatment options, surge in number of people seeking treatment, and rising approvals by regulatory authorities. For instance, in January 2022, The US Food and Drug Administration (FDA) has granted Oncolyze Inc. an orphan drug designation for OM-301, which is intended to be used in the treatment of acute myeloid leukemia (AML). Additionally, online providers is predicted to grow at fastest CAGR during the forecast period owing to the availability of a variety of alternatives and ongoing services, a growth in e-commerce sales, better logistical services, and more convenient payment methods.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of leukaemia, increasing advancements in the treatment of leukaemia, rising government initiatives, and growing partnerships & collaborations within market players. For instance, in November 2022, The Canadian Cancer Society (CCS) has revealed a collaboration with CQDM, the Cole Foundation, and Oncopole, pôle cancer du FRQS, to establish a new four-year grant program with a total value of up to USD 5 million. This partnership signifies the joint funding of research initiatives in Quebec by CCS and its partners. The program is aimed at expediting the advancement of platforms, tools, and therapies to promote progress across the spectrum of pediatric cancer care, including prevention, diagnosis, and treatment. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising healthcare infrastructure, surge in contract manufacturing organizations, increasing personalized medicine expenditure, growing adoption of high-tech processing to improve the production of leukemia therapeutics, and rising research & development activities. For instance, in January 2022, Chinese scientists have identified a potential treatment for leukemia by introducing nanoparticles into the bloodstream through infusion.
Rising approval of novel drugs for leukaemia by regulatory authorities is predicted to boost the market growth during the forecast period. Leukemia is a form of blood cancer characterized by the abnormal growth of leukocytes. Acute and chronic leukemia are the two categories of leukemia. This condition leads to a shortage of healthy blood cells, resulting in various symptoms like bleeding, bruising, bone pain, fatigue, and fever. Consequently, industry stakeholders are concentrating on the creation of novel treatment alternatives. For instance, in May 2022, Servier has obtained approval from the US FDA for TIBSOVO (ivosidenib tablets) to be used in combination with azacitidine for treating newly diagnosed IDH1-mutated acute myeloid leukemia (AML) in adults aged 75 years or older, or in those with medical conditions that make them unsuitable for intensive induction chemotherapy.
By type, chronic myeloid leukaemia was the highest revenue-grossing segment in the global leukemia therapeutics market in 2023 owing to rising prevalence of chronic myeloid leukaemia, growing geriatric population, and increasing funding for research & development activities. Additionally, chronic lymphocytic leukaemia is predicted to grow at fastest CAGR during the forecast period owing to the growing prevalence of chronic lymphocytic leukaemia and surge in approvals by regulatory bodies. For instance, in November 2022, The use of Brukinsa (zanubrutinib) in the treatment of adult patients with either treatment-naive (TN) or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) has been approved by the European Council, according to information released by BeiGene.
By treatment, chemotherapy was the highest revenue-grossing segment in the global leukemia therapeutics market in 2023 owing to the growing prevalence of leukemia cases, rising focus on development of novel products for the treatment of leukaemia, and increasing approvals by regulatory bodies. For instance, in October 2022, The US FDA has granted approval for Quizartinib to be used in conjunction with standard cytarabine and anthracycline induction, as well as standard cytarabine consolidation chemotherapy. It is also approved for use as a continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD-positive acute myeloid leukemia (AML). Additionally, targeted therapy is predicted to grow at fastest CAGR during the forecast period owing to the fewer side effects of this therapy, rising demand for targeted drugs, and increasing launch of novel drugs.
By route of administration, injectable was the highest revenue-grossing segment in the global leukemia therapeutics market in 2023 owing to the increasing research & development activities and surge in clinical trial procedures. For instance, in October 2023, Syndax Pharmaceuticals has reported that Revumenib has successfully achieved its objectives in the trial, potentially paving the way for the drug's introduction to the market. Additionally, oral is predicted to grow at fastest CAGR during the forecast period owing to the ease of administration and growing focus on development of new drugs.
By distribution channel, hospital pharmacies was the highest revenue-grossing segment in the global leukemia therapeutics market in 2023 owing to the increasing awareness regarding leukemia & treatment options, surge in number of people seeking treatment, and rising approvals by regulatory authorities. For instance, in January 2022, The US Food and Drug Administration (FDA) has granted Oncolyze Inc. an orphan drug designation for OM-301, which is intended to be used in the treatment of acute myeloid leukemia (AML). Additionally, online providers is predicted to grow at fastest CAGR during the forecast period owing to the availability of a variety of alternatives and ongoing services, a growth in e-commerce sales, better logistical services, and more convenient payment methods.
North America region is anticipated for the highest revenue share during the forecast period owing to the surge in prevalence of leukaemia, increasing advancements in the treatment of leukaemia, rising government initiatives, and growing partnerships & collaborations within market players. For instance, in November 2022, The Canadian Cancer Society (CCS) has revealed a collaboration with CQDM, the Cole Foundation, and Oncopole, pôle cancer du FRQS, to establish a new four-year grant program with a total value of up to USD 5 million. This partnership signifies the joint funding of research initiatives in Quebec by CCS and its partners. The program is aimed at expediting the advancement of platforms, tools, and therapies to promote progress across the spectrum of pediatric cancer care, including prevention, diagnosis, and treatment. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising healthcare infrastructure, surge in contract manufacturing organizations, increasing personalized medicine expenditure, growing adoption of high-tech processing to improve the production of leukemia therapeutics, and rising research & development activities. For instance, in January 2022, Chinese scientists have identified a potential treatment for leukemia by introducing nanoparticles into the bloodstream through infusion.
Segmentation: Leukemia Therapeutics Market Report 2023 - 2034
Leukemia Therapeutics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Chronic Lymphocytic Leukaemia
- Acute Myeloid Leukaemia
- Chronic Myeloid Leukaemia
- Acute Lymphocytic Leukaemia
- Other
Leukemia Therapeutics Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- Targeted Therapy
- Immunotherapy
- Chemotherapy
- Other
Leukemia Therapeutics Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Oral
- Injectable
Leukemia Therapeutics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Online Providers
- Drug Stores & Retail Pharmacies
Leukemia Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Leukemia Therapeutics Market: Type Estimates & Trend Analysis
8. Leukemia Therapeutics Market: Treatment Estimates & Trend Analysis
9. Leukemia Therapeutics Market: Route of Administration Estimates & Trend Analysis
10. Leukemia Therapeutics Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Leukemia Therapeutics Market
13. Europe Global Leukemia Therapeutics Market
14. Asia Pacific Global Leukemia Therapeutics Market
15. Latin America Global Leukemia Therapeutics Market
16. MEA Global Leukemia Therapeutics Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Lupin
- Novartis AG
- Bristol-Myers Squibb Company
- Abbvie Inc
- Pfizer Inc.
- Sanofi
- Gilead Sciences Inc.
- Amgen Inc.
- Teva Pharmaceutical Industries Limited
- Takeda Pharmaceutical Company Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 16.35 Billion |
| Forecasted Market Value ( USD | $ 35.28 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
